Karyopharm Therapeutics (KPTI) Tops Q1 EPS by 7c; Offers FY23 Revenue Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $38.7 million versus the consensus estimate of $36.3 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2023 revenue of $145-160 million, versus the consensus of $157.4 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• HP Inc. projects mid-single-digit PC market decline in 2027
• CLSA Reiterates Outperform (2) Rating on CSL Ltd. (CSL:AU) (CMXHF)
• Citi lowers East West Bancorp price target to $152